We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 81

Generic Health succeeds in invalidating patent for aripiprazole: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) 2015 FCA 634
  • King & Wood Mallesons
  • Australia
  • July 7 2015

Generic Health is perhaps a step closer to bringing its generic version of the antipsychotic drug aripiprazole to market in Australia after Justice


Australian case notes - Odisho v Bonazzi 2014 VSCA 11
  • King & Wood Mallesons
  • Australia
  • May 20 2014

In this case the appellant, a patient who suffered a thromboembolic event following the use of tranexamic acid, claimed that her doctor had


The image of deception
  • King & Wood Mallesons
  • Australia
  • March 14 2014

On 10 March 2014, the Federal Court of Australia found that Breast Check Pty Ltd engaged in misleading or deceptive conduct and made false


Those drugs cost how much?? Chemist warehouse price list misleading but not for the reasons you might think
  • King & Wood Mallesons
  • Australia
  • October 29 2012

Last Monday the Supreme Court of Queensland held that a price list published by various Chemist Warehouse pharmacies in Cairns, Nerang, Coolangatta and other parts of Queensland was likely to mislead or deceive and therefore contravene clause 18 of the Australian Consumer Law (Competition and Consumer Act 2010 (Cth), schedule 2, section 18


Homeopathy plus! Not immune from the ACL
  • King & Wood Mallesons
  • Australia
  • March 7 2013

On 21 February 2013, the ACCC instituted proceedings against Homeopathy Plus! Australia Pty Ltd ("Homeopathy Plus!") in the Federal Court of


Australian court decides important gene patenting question isolated genetic material patentable subject matter
  • King & Wood Mallesons
  • Australia
  • February 15 2013

Earlier today, the Federal Court rejected a claim brought by Cancer Voices Australia that isolated genetic material (DNA or RNA) that is naturally


Experimental evidence comply with the rules or risk inadmissibility
  • King & Wood Mallesons
  • Australia
  • March 22 2013

By refusing to allow Generic Health to adduce experimental evidence in a patent case currently being heard in the Federal Court, Justice Jagot has


Federal Court holds that employers can require employees to provide medical reports and undergo medical examinations
  • King & Wood Mallesons
  • Australia
  • March 25 2014

The Federal Court has provided guidance on when an employer can require an employee to obtain a medical report or undergo a medical examination in


Blockbuster drug goes bust? The Federal Court finds three AstraZeneca patents relating to Crestor (rosuvastatin) invalid
  • King & Wood Mallesons
  • Australia
  • March 7 2013

In an important decision handed down on Tuesday, Justice Jagot of the Federal Court held that three patents relating to the blockbuster drug Crestor


Competition regulators continue their campaign against pharmaceutical companies
  • King & Wood Mallesons
  • Australia, USA
  • June 1 2011

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year